GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of NxStage Medical, Inc. (NASDAQ:NXTM) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 256,282 shares of the medical device company’s stock, valued at approximately $7,073,000. GABELLI & Co INVESTMENT ADVISERS INC. owned approximately 0.39% of NxStage Medical as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Suntrust Banks Inc. increased its holdings in shares of NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after acquiring an additional 209 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of NxStage Medical by 1.1% during the first quarter. Principal Financial Group Inc. now owns 28,191 shares of the medical device company’s stock valued at $757,000 after acquiring an additional 303 shares in the last quarter. Amalgamated Bank increased its holdings in shares of NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after acquiring an additional 553 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of NxStage Medical by 3.5% during the second quarter. Legal & General Group Plc now owns 25,349 shares of the medical device company’s stock valued at $630,000 after acquiring an additional 856 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of NxStage Medical by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 50,336 shares of the medical device company’s stock valued at $1,262,000 after acquiring an additional 1,059 shares in the last quarter. Hedge funds and other institutional investors own 91.19% of the company’s stock.

In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $29.21, for a total transaction of $102,235.00. Following the transaction, the senior vice president now owns 16,270 shares in the company, valued at approximately $475,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $29.26, for a total value of $29,260.00. Following the transaction, the president now owns 74,903 shares in the company, valued at approximately $2,191,661.78. The disclosure for this sale can be found here. Insiders have sold a total of 18,600 shares of company stock worth $526,162 in the last quarter. Company insiders own 4.70% of the company’s stock.

Several equities research analysts have recently commented on NXTM shares. BidaskClub downgraded NxStage Medical from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Craig Hallum downgraded NxStage Medical from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Northland Securities restated a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a report on Monday, August 7th. Canaccord Genuity downgraded NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price objective for the company. in a report on Monday, August 7th. Finally, William Blair downgraded NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating and eight have issued a hold rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $30.25.

TRADEMARK VIOLATION NOTICE: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/256282-shares-in-nxstage-medical-inc-nxtm-acquired-by-gabelli-co-investment-advisers-inc/1683402.html.

Shares of NxStage Medical, Inc. (NASDAQ NXTM) traded down $0.01 during trading on Monday, reaching $26.64. The company had a trading volume of 105,636 shares, compared to its average volume of 630,075. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.03) EPS. analysts forecast that NxStage Medical, Inc. will post -0.06 EPS for the current fiscal year.

NxStage Medical Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.